\-\ Texto\\:\\ \ \(0\)\
\-\ \\â\\€\\¢\\ unremarkable\\ physical\\ exam\ \(0\)\
\-\ \\â\\€\\¢\\ laboratory\\ studies\\ within\\ normal\\ limits\ \(0\)\
\-\ \\â\\€\\¢\\ long\\-term\\ observation\\ with\\ interval\\ imaging\\ to\\ assess\\ for\\ progression\\ of\\ the\\ lesion\ \(0\)\
\-\ \\â\\€\\¢\\ medical\\ management\\ of\\ symptoms\\ \\(i\\.e\\.\\ pain\\ control\\)\ \(0\)\
\-\ \\â\\€\\¢\\ bisphosphonates\\ have\\ been\\ shown\\ to\\ reduce\\ bone\\ pain\ \(0\)\
\-\ \\â\\€\\¢\\ surgery\\ may\\ be\\ considered\\ for\\ complicated\\ lesions\\ with\\ mass\\ effect\\ and\\/or\\ resulting\\ fractures\ \(0\)\
\-\ ct\\ head\\ without\\ contrast\\:\\ expansile\\ ground\\ glass\\ lesion\\ involving\\ the\\ ethmoid\\ bone\\ and\\ crista\\ galli\\ with\\ extension\\ into\\ the\\ sphenoid\\ sinuses\\ with\\ mass\\ effect\\ on\\ the\\ medial\\ right\\ orbit\\ favored\\ to\\ represent\\ fibrous\\ dysplasia\\.\ \(0\)\
\-\ follow\\-up\\ ct\\ of\\ the\\ orbits\\ and\\ sinuses\\:\\ the\\ known\\ fibrous\\ dysplasia\\ is\\ again\\ seen\\ involving\\ the\\ crista\\ galli\\ and\\ ethmoid\\ bone\\ with\\ extension\\ into\\ the\\ sphenoid\\ sinuses\\.\\ minimal\\ interval\\ expansion\\ of\\ the\\ fibrous\\ dysplastic\\ lesion\\ of\\ the\\ ethmoid\\ bone\\ and\\ crista\\ galli\\ into\\ the\\ medial\\ right\\ orbit\\.\\ \ \(0\)\
\-\ bone\\ scan\\:\\ moderately\\ intense\\ tracer\\ activity\\ in\\ the\\ region\\ of\\ the\\ previously\\ described\\ ground\\-glass\\,\\ expansile\\ lesion\\ centered\\ on\\ the\\ ethmoid\\ air\\ cells\\,\\ involving\\ the\\ crista\\ galli\\ and\\ extending\\ into\\ the\\ sphenoid\\ sinuses\ \(0\)\
\-\ fibrous\\ dysplasia\ \(50\)\
\-\ \\â\\€\\¢\\ enchondroma\\ and\\ enchondromatosis\ \(0\)\
\-\ \\â\\€\\¢\\ eosinophilic\\ granuloma\\ \\(skeletal\\)\ \(0\)\
\-\ \\â\\€\\¢\\ fibrous\\ cortical\\ defect\\ and\\ nonossifying\\ fibroma\ \(0\)\
\-\ \\â\\€\\¢\\ giant\\ cell\\ tumor\ \(1\)\
\-\ \\â\\€\\¢\\ bone\\ hemangioma\ \(0\)\
\-\ \\â\\€\\¢\\ primary\\ hyperparathyroidism\ \(0\)\
\-\ \\â\\€\\¢\\ neurofibromatosis\\ type\\ i\ \(0\)\
\-\ \\â\\€\\¢\\ paget\\ disease\ \(0\)\
\-\ \\â\\€\\¢\\ metastases\ \(0\)\
\-\ 54\\ year\\ old\\ woman\\ with\\ headache\\ and\\ syncope\ \(1\)\
\-\ fibrous\\ dysplasia\\ is\\ a\\ skeletal\\ developmental\\ anomaly\\ of\\ the\\ bone\\-forming\\ mesenchyme\\ resulting\\ from\\ abnormal\\ osteoblast\\ function\\.\\ fibrous\\ dysplasia\\ is\\ a\\ nonheritable\\ disease\\ related\\ to\\ a\\ sporadic\\ mutation\\ in\\ the\\ gene\\ that\\ encodes\\ the\\ subunit\\ of\\ a\\ stimulatory\\ g\\ protein\\ on\\ chromosome\\ 20\\.\\ as\\ a\\ result\\,\\ osteoblasts\\ abnormally\\ produce\\ fibrous\\ tissue\\ within\\ the\\ bone\\ marrow\\.\\ fracture\\ is\\ the\\ most\\ common\\ complication\\ of\\ fibrous\\ dysplasia\\.\\ malignant\\ transformation\\ occurs\\ less\\ than\\ 0\\.5\\%\\ of\\ cases\\.\\ \ \(0\)\
\-\ fibrous\\ dysplasia\\ represents\\ approximately\\ 5\\%\\ of\\ all\\ benign\\ bone\\ tumors\\.\\ any\\ bone\\ can\\ be\\ affected\\.\\ 70\\%\\ of\\ cases\\ are\\ the\\ monostotic\\ form\\ whereas\\ 30\\%\\ are\\ of\\ the\\ polystotic\\ form\\.\\ the\\ incidence\\ rates\\ are\\ equal\\ in\\ males\\ and\\ females\\.\\ however\\ the\\ true\\ incidence\\ is\\ unknown\\ since\\ many\\ patients\\ are\\ asymptomatic\\.\\ \\ fibrous\\ dysplasia\\ usually\\ presents\\ in\\ persons\\ aged\\ 3\\-15\\.\\ most\\ cases\\ manifest\\ themselves\\ before\\ the\\ age\\ of\\ 30\\.\\ clinically\\ patients\\ present\\ with\\ pain\\ and\\ deformity\\ or\\ with\\ a\\ pathologic\\ fracture\\.\\ long\\ bones\\ are\\ commonly\\ affected\\.\\ the\\ femur\\ is\\ the\\ most\\ common\\ long\\ bone\\ affected\\.\\ other\\ common\\ areas\\ include\\ the\\ tibia\\,\\ facial\\ bones\\ and\\ skull\\.\\ \ \(0\)\
\-\ the\\ diagnosis\\ is\\ typically\\ made\\ with\\ plain\\ radiography\\.\\ characteristic\\ radiographic\\ findings\\ include\\ a\\ relatively\\ homogenous\\ lucent\\ lesion\\ with\\ or\\ without\\ bone\\ expansion\\ commonly\\ described\\ as\\ a\\ ground\\-glass\\ appearance\\.\\ additionally\\ the\\ lucent\\ lesion\\ has\\ a\\ thick\\ sclerotic\\ border\\ that\\ is\\ called\\ the\\ rind\\ sign\\.\\ there\\ should\\ be\\ an\\ absence\\ of\\ periosteal\\ reaction\\.\\ ct\\ is\\ commonly\\ used\\ to\\ assess\\ complex\\ areas\\ such\\ as\\ the\\ spine\\,\\ pelvis\\,\\ chest\\ and\\ craniofacial\\ bones\\.\\ ct\\ is\\ very\\ useful\\ in\\ evaluating\\ the\\ extent\\ of\\ disease\\ in\\ these\\ complex\\ areas\\.\\ nuclear\\ imaging\\ may\\ also\\ be\\ used\\ in\\ conjunction\\ with\\ other\\ imaging\\ modalities\\ to\\ assist\\ with\\ the\\ diagnosis\\ of\\ fibrous\\ dysplasia\\.\\ however\\ nuclear\\ imaging\\ is\\ not\\ specific\\ for\\ fibrous\\ dysplasia\\.\\ needle\\ biopsy\\ can\\ be\\ used\\ to\\ confirm\\ the\\ diagnosis\\ if\\ there\\ is\\ uncertainty\\.\ \(0\)\
\-\ asymptomatic\\ patients\\ do\\ not\\ require\\ treatment\\.\\ bisphosphonates\\ have\\ been\\ shown\\ to\\ be\\ helpful\\ treating\\ chronic\\ bone\\ pain\\ associated\\ with\\ fibrous\\ dysplasia\\.\\ surgical\\ treatment\\ is\\ indicated\\ for\\ the\\ treatment\\ and\\ prevention\\ of\\ pathologic\\ fractures\\.\\ surgery\\ may\\ also\\ be\\ utilized\\ for\\ the\\ treatment\\ of\\ severe\\ deformity\\.\ \(0\)\
\-\ references\\:\ \(0\)\
\-\ anand\\ mkn\\.\\ fibrous\\ dysplasia\\.\\<http\\:\\/\\/emedicine\\.medscape\\.com\\>\\ accessed\\ 01nov2009\\.\ \(0\)\
\-\ grossman\\ ri\\ and\\ yousem\\ dm\\.\\ neuroradiology\\:\\ the\\ requisites\\ 2nd\\ edition\\.\\ mosby\\ 2003\\.\\ \ \(0\)\
\-\ vargas\\ b\\,\\ and\\ clayer\\ m\\.\\ fibrous\\ dysplasia\\.\\ \\<http\\:\\/\\/imedicine\\.com\\>\\ accessed\\ 01nov2009\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ fibrous\\:\\ 0\\.0855535915357789\ \(0\)\
\-\ dysplasia\\:\\ 0\\.06265821758720813\ \(0\)\
\-\ crista\\:\\ 0\\.05029332039261024\ \(0\)\
\-\ galli\\:\\ 0\\.05029332039261024\ \(0\)\
\-\ bone\\:\\ 0\\.03944460708594186\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.03638578215779926\ \(0\)\
\-\ ethmoid\\:\\ 0\\.030878495526175873\ \(0\)\
\-\ 01nov2009\\:\\ 0\\.027292626699586684\ \(0\)\
\-\ sinuses\\:\\ 0\\.027224011245634058\ \(0\)\
\-\ sphenoid\\:\\ 0\\.02208239356077436\ \(0\)\
\-\ bisphosphonates\\:\\ 0\\.019868802325597918\ \(0\)\
\-\ ground\\-glass\\:\\ 0\\.01890857034942504\ \(0\)\
\-\ affected\\:\\ 0\\.017171166926701596\ \(0\)\
\-\ accessed\\:\\ 0\\.01697620406746531\ \(0\)\
\-\ bones\\:\\ 0\\.016746279896865685\ \(0\)\
\-\ lesion\\:\\ 0\\.016166147609911342\ \(0\)\
\-\ used\\:\\ 0\\.015223765434742857\ \(0\)\
\-\ commonly\\:\\ 0\\.014974604226574185\ \(0\)\
\-\ be\\:\\ 0\\.014279097621373846\ \(0\)\
\-\ lucent\\:\\ 0\\.014139390656090215\ \(0\)\
\-\ involving\\:\\ 0\\.013924491938095791\ \(0\)\
\-\ nuclear\\:\\ 0\\.013649533054805712\ \(0\)\
\-\ bone\\-forming\\:\\ 0\\.013646313349793342\ \(0\)\
\-\ osteoblast\\:\\ 0\\.013646313349793342\ \(0\)\
\-\ nonheritable\\:\\ 0\\.013646313349793342\ \(0\)\
\-\ polystotic\\:\\ 0\\.013646313349793342\ \(0\)\
\-\ 3\\-15\\.\\:\\ 0\\.013646313349793342\ \(0\)\
\-\ anand\\:\\ 0\\.013646313349793342\ \(0\)\
\-\ mkn\\:\\ 0\\.013646313349793342\ \(0\)\
\-\ dysplasia\\.\\:\\ 0\\.013646313349793342\ \(0\)\
\-\ vargas\\:\\ 0\\.013646313349793342\ \(0\)\
\-\ \\/\\/imedicine\\.com\\:\\ 0\\.013646313349793342\ \(0\)\
\-\ areas\\:\\ 0\\.01335300543922322\ \(0\)\
\-\ orbit\\:\\ 0\\.013327117391484981\ \(0\)\
\-\ assess\\:\\ 0\\.013259810931310347\ \(0\)\
\-\ cases\\:\\ 0\\.013220483888457271\ \(0\)\
\-\ skeletal\\:\\ 0\\.013066249454587953\ \(0\)\
\-\ expansion\\:\\ 0\\.013035133863710238\ \(0\)\
\-\ interval\\:\\ 0\\.012973825420068814\ \(0\)\
\-\ expansile\\:\\ 0\\.012973825420068814\ \(0\)\
\-\ into\\:\\ 0\\.012590256148357319\ \(0\)\
\-\ encodes\\:\\ 0\\.01257333009815256\ \(0\)\
\-\ subunit\\:\\ 0\\.01257333009815256\ \(0\)\
\-\ stimulatory\\:\\ 0\\.01257333009815256\ \(0\)\
\-\ \\/\\/emedicine\\.medscape\\.com\\:\\ 0\\.01257333009815256\ \(0\)\
\-\ grossman\\:\\ 0\\.01257333009815256\ \(0\)\
\-\ yousem\\:\\ 0\\.01257333009815256\ \(0\)\
\-\ clayer\\:\\ 0\\.01257333009815256\ \(0\)\
\-\ imaging\\:\\ 0\\.012396741947093516\ \(0\)\
\-\ form\\:\\ 0\\.012369154360252203\ \(0\)\
\-\ \\%\\:\\ 0\\.012342545098117694\ \(0\)\
\-\ \\:\\:\\ 0\\.012247559925595442\ \(0\)\
\-\ incidence\\:\\ 0\\.012129035987664356\ \(0\)\
\-\ mesenchyme\\:\\ 0\\.01194567513204085\ \(0\)\
\-\ uncertainty\\:\\ 0\\.01194567513204085\ \(0\)\
\-\ resulting\\:\\ 0\\.011618957866685856\ \(0\)\
\-\ pathologic\\:\\ 0\\.011580014268522202\ \(0\)\
\-\ osteoblasts\\:\\ 0\\.011500346846511777\ \(0\)\
\-\ deformity\\:\\ 0\\.011392321940917141\ \(0\)\
\-\ is\\:\\ 0\\.011315449100621414\ \(0\)\
\-\ described\\:\\ 0\\.01126739532938907\ \(0\)\
\-\ persons\\:\\ 0\\.011154923392465012\ \(0\)\
\-\ ri\\:\\ 0\\.011154923392465012\ \(0\)\
\-\ 30\\.\\:\\ 0\\.010872691880400067\ \(0\)\
\-\ craniofacial\\:\\ 0\\.010872691880400067\ \(0\)\
\-\ treatment\\:\\ 0\\.010709702536228403\ \(0\)\
\-\ rind\\:\\ 0\\.01063406853701422\ \(0\)\
\-\ shown\\:\\ 0\\.010608194099535596\ \(0\)\
\-\ complex\\:\\ 0\\.010594089404378133\ \(0\)\
\-\ monostotic\\:\\ 0\\.010427363594870995\ \(0\)\
\-\ common\\:\\ 0\\.010385141851190698\ \(0\)\
\-\ patients\\:\\ 0\\.010270470275693618\ \(0\)\
\-\ \\<\\:\\ 0\\.010210729187312046\ \(0\)\
\-\ fractures\\:\\ 0\\.010017921355976086\ \(0\)\
\-\ http\\:\\ 0\\.010017921355976086\ \(0\)\
\-\ themselves\\:\\ 0\\.009934401162798959\ \(0\)\
\-\ chromosome\\:\\ 0\\.009799708628759285\ \(0\)\
\-\ neuroradiology\\:\\ 0\\.009675803508521612\ \(0\)\
\-\ favored\\:\\ 0\\.009561085285373437\ \(0\)\
\-\ enchondromatosis\\:\\ 0\\.009561085285373437\ \(0\)\
\-\ 2003\\.\\:\\ 0\\.009561085285373437\ \(0\)\
\-\ prevention\\:\\ 0\\.00945428517471252\ \(0\)\
\-\ extension\\:\\ 0\\.009443737836475709\ \(0\)\
\-\ effect\\:\\ 0\\.009367053415075061\ \(0\)\
\-\ 20\\.\\:\\ 0\\.009354380343230212\ \(0\)\
\-\ most\\:\\ 0\\.009161773104000353\ \(0\)\
\-\ long\\:\\ 0\\.009121428826107504\ \(0\)\
\-\ diagnosis\\:\\ 0\\.00911247367235489\ \(0\)\
\-\ manifest\\:\\ 0\\.0090883582736843\ \(0\)\
\-\ assist\\:\\ 0\\.0090883582736843\ \(0\)\
\-\ are\\:\\ 0\\.009016051644965958\ \(0\)\
\-\ syncope\\:\\ 0\\.009008956889183448\ \(0\)\
\-\ conjunction\\:\\ 0\\.009008956889183448\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.008943010520111726\ \(0\)\
\-\ gene\\:\\ 0\\.008861417911158177\ \(0\)\
\-\ \\>\\:\\ 0\\.008789992305475431\ \(0\)\
\-\ nonossifying\\:\\ 0\\.008726725377118503\ \(0\)\
\-\ aged\\:\\ 0\\.008726725377118503\ \(0\)\
\-\ may\\:\\ 0\\.008704311310672402\ \(0\)\
\-\ tracer\\:\\ 0\\.008663533435136683\ \(0\)\
\-\ orbits\\:\\ 0\\.00860282025688083\ \(0\)\
\-\ sporadic\\:\\ 0\\.008544398696535865\ \(0\)\
\-\ requisites\\:\\ 0\\.008544398696535865\ \(0\)\
\-\ medial\\:\\ 0\\.008462227596254032\ \(0\)\
\-\ mutation\\:\\ 0\\.008433781105232236\ \(0\)\
\-\ utilized\\:\\ 0\\.008381301923071738\ \(0\)\
\-\ dm\\:\\ 0\\.008381301923071738\ \(0\)\
\-\ the\\:\\ 0\\.008346319045574932\ \(0\)\
\-\ dysplastic\\:\\ 0\\.008330543683407667\ \(0\)\
\-\ 0\\.5\\:\\ 0\\.0081875509277869\ \(0\)\
\-\ treating\\:\\ 0\\.0081875509277869\ \(0\)\
\-\ modalities\\:\\ 0\\.007935973637542665\ \(0\)\
\-\ edition\\:\\ 0\\.00789774977904364\ \(0\)\
\-\ enchondroma\\:\\ 0\\.007860447067620943\ \(0\)\
\-\ whereas\\:\\ 0\\.007860447067620943\ \(0\)\
\-\ homogenous\\:\\ 0\\.007860447067620943\ \(0\)\
\-\ g\\:\\ 0\\.007824022149029313\ \(0\)\
\-\ mosby\\:\\ 0\\.007788434659517395\ \(0\)\
\-\ centered\\:\\ 0\\.00775364695696003\ \(0\)\
\-\ m\\.\\:\\ 0\\.00775364695696003\ \(0\)\
\-\ rates\\:\\ 0\\.007686332542192632\ \(0\)\
\-\ glass\\:\\ 0\\.007653742125477721\ \(0\)\
\-\ males\\:\\ 0\\.007621823724235095\ \(0\)\
\-\ moderately\\:\\ 0\\.00755989596167519\ \(0\)\
\-\ radiography\\:\\ 0\\.007529837005240047\ \(0\)\
\-\ transformation\\:\\ 0\\.0075003506353163735\ \(0\)\
\-\ reduce\\:\\ 0\\.007471415444895084\ \(0\)\
\-\ include\\:\\ 0\\.007421527826719155\ \(0\)\
\-\ ct\\:\\ 0\\.007401261011715437\ \(0\)\
\-\ however\\:\\ 0\\.007366464568411983\ \(0\)\
\-\ fibroma\\:\\ 0\\.007360797853591454\ \(0\)\
\-\ females\\:\\ 0\\.007360797853591454\ \(0\)\
\-\ evaluating\\:\\ 0\\.007360797853591454\ \(0\)\
\-\ paget\\:\\ 0\\.007334335882447026\ \(0\)\
\-\ produce\\:\\ 0\\.007334335882447026\ \(0\)\
\-\ long\\-term\\:\\ 0\\.007308318671430957\ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.007308318671430957\ \(0\)\
\-\ ground\\:\\ 0\\.00728273151670772\ \(0\)\
\-\ abnormally\\:\\ 0\\.00728273151670772\ \(0\)\
\-\ true\\:\\ 0\\.007257560431766884\ \(0\)\
\-\ been\\:\\ 0\\.007197507397721336\ \(0\)\
\-\ eosinophilic\\:\\ 0\\.007091968915432258\ \(0\)\
\-\ i\\.e\\:\\ 0\\.0070696953280451075\ \(0\)\
\-\ intense\\:\\ 0\\.00700473526752029\ \(0\)\
\-\ 54\\:\\ 0\\.006983673886628992\ \(0\)\
\-\ fracture\\:\\ 0\\.0069754623228259404\ \(0\)\
\-\ hyperparathyroidism\\:\\ 0\\.006942391770402736\ \(0\)\
\-\ thick\\:\\ 0\\.006942391770402736\ \(0\)\
\-\ called\\:\\ 0\\.006942391770402736\ \(0\)\
\-\ equal\\:\\ 0\\.0069221563500198365\ \(0\)\
\-\ useful\\:\\ 0\\.006902182039128339\ \(0\)\
\-\ complicated\\:\\ 0\\.006862990385901883\ \(0\)\
\-\ helpful\\:\\ 0\\.006843760478783374\ \(0\)\
\-\ observation\\:\\ 0\\.006787463815980162\ \(0\)\
\-\ protein\\:\\ 0\\.006787463815980162\ \(0\)\
\-\ needle\\:\\ 0\\.006733142887479744\ \(0\)\
\-\ confirm\\:\\ 0\\.006733142887479744\ \(0\)\
\-\ 2nd\\:\\ 0\\.006596968316355972\ \(0\)\
\-\ progression\\:\\ 0\\.0065807588738369385\ \(0\)\
\-\ extent\\:\\ 0\\.006564717407837641\ \(0\)\
\-\ anomaly\\:\\ 0\\.006548840472594313\ \(0\)\
\-\ granuloma\\:\\ 0\\.006502163942918327\ \(0\)\
\-\ complication\\:\\ 0\\.006486912710034407\ \(0\)\
\-\ disease\\:\\ 0\\.006486397250227728\ \(0\)\
\-\ pain\\:\\ 0\\.006461970077589689\ \(0\)\
\-\ surgery\\:\\ 0\\.00642414571009373\ \(0\)\
\-\ giant\\:\\ 0\\.006370027953829848\ \(0\)\
\-\ again\\:\\ 0\\.006356018920517283\ \(0\)\
\-\ represents\\:\\ 0\\.006356018920517283\ \(0\)\
\-\ 70\\:\\ 0\\.006356018920517283\ \(0\)\
\-\ border\\:\\ 0\\.006301217175856422\ \(0\)\
\-\ periosteal\\:\\ 0\\.0062745270730166286\ \(0\)\
\-\ b\\:\\ 0\\.006235335419790175\ \(0\)\
\-\ without\\:\\ 0\\.006229142929901425\ \(0\)\
\-\ developmental\\:\\ 0\\.0061475717298884016\ \(0\)\
\-\ other\\:\\ 0\\.006097952163165476\ \(0\)\
\-\ tibia\\:\\ 0\\.006076113460905178\ \(0\)\
\-\ require\\:\\ 0\\.006053008739207537\ \(0\)\
\-\ control\\:\\ 0\\.006030243805167761\ \(0\)\
\-\ reaction\\:\\ 0\\.0060078088093433535\ \(0\)\
\-\ as\\:\\ 0\\.006002681915917002\ \(0\)\
\-\ can\\:\\ 0\\.006000688397737058\ \(0\)\
\-\ sclerotic\\:\\ 0\\.005921185506482604\ \(0\)\
\-\ hemangioma\\:\\ 0\\.005910690634988209\ \(0\)\
\-\ marrow\\:\\ 0\\.0058193074591612855\ \(0\)\
\-\ represent\\:\\ 0\\.005809478933342928\ \(0\)\
\-\ clinically\\:\\ 0\\.0057997124175638804\ \(0\)\
\-\ facial\\:\\ 0\\.005751783275762074\ \(0\)\
\-\ do\\:\\ 0\\.005742372987718139\ \(0\)\
\-\ additionally\\:\\ 0\\.005733019559767733\ \(0\)\
\-\ have\\:\\ 0\\.0057289104593346496\ \(0\)\
\-\ indicated\\:\\ 0\\.0057237223089005316\ \(0\)\
\-\ femur\\:\\ 0\\.00571448056433938\ \(0\)\
\-\ relatively\\:\\ 0\\.005660159635838962\ \(0\)\
\-\ metastases\\:\\ 0\\.005651288622357561\ \(0\)\
\-\ for\\:\\ 0\\.005643251924479219\ \(0\)\
\-\ skull\\:\\ 0\\.005633697664694535\ \(0\)\
\-\ function\\:\\ 0\\.005607680453678465\ \(0\)\
\-\ before\\:\\ 0\\.005599104323066057\ \(0\)\
\-\ characteristic\\:\\ 0\\.005599104323066057\ \(0\)\
\-\ and\\/or\\:\\ 0\\.005590575444101707\ \(0\)\
\-\ previously\\:\\ 0\\.005556922214014392\ \(0\)\
\-\ a\\:\\ 0\\.005525384235862866\ \(0\)\
\-\ absence\\:\\ 0\\.005499734110002497\ \(0\)\
\-\ references\\:\\ 0\\.005499734110002497\ \(0\)\
\-\ i\\:\\ 0\\.005467979404378498\ \(0\)\
\-\ specific\\:\\ 0\\.005467979404378498\ \(0\)\
\-\ related\\:\\ 0\\.005460141475653194\ \(0\)\
\-\ limits\\:\\ 0\\.005452343032882363\ \(0\)\
\-\ many\\:\\ 0\\.005436863027720468\ \(0\)\
\-\ occurs\\:\\ 0\\.005429180691277544\ \(0\)\
\-\ considered\\:\\ 0\\.005339848930254872\ \(0\)\
\-\ cells\\:\\ 0\\.005304097049767798\ \(0\)\
\-\ to\\:\\ 0\\.005288769144804784\ \(0\)\
\-\ made\\:\\ 0\\.005269152278810307\ \(0\)\
\-\ also\\:\\ 0\\.005215540537678487\ \(0\)\
\-\ minimal\\:\\ 0\\.005208173328793805\ \(0\)\
\-\ unknown\\:\\ 0\\.005162352168149391\ \(0\)\
\-\ 30\\:\\ 0\\.00508682559822767\ \(0\)\
\-\ result\\:\\ 0\\.005074588478247619\ \(0\)\
\-\ within\\:\\ 0\\.005046846465591584\ \(0\)\
\-\ radiographic\\:\\ 0\\.005020687912985656\ \(0\)\
\-\ management\\:\\ 0\\.004991534742191396\ \(0\)\
\-\ tumors\\:\\ 0\\.004968601172864553\ \(0\)\
\-\ activity\\:\\ 0\\.004962920477989998\ \(0\)\
\-\ defect\\:\\ 0\\.004951621248142302\ \(0\)\
\-\ studies\\:\\ 0\\.0049404038974909595\ \(0\)\
\-\ laboratory\\:\\ 0\\.004874755009062022\ \(0\)\
\-\ since\\:\\ 0\\.0048587687642387255\ \(0\)\
\-\ cortical\\:\\ 0\\.0048220972919130215\ \(0\)\
\-\ pelvis\\:\\ 0\\.004806643044259488\ \(0\)\
\-\ very\\:\\ 0\\.0048015257251658346\ \(0\)\
\-\ malignant\\:\\ 0\\.0047812239572435\ \(0\)\
\-\ biopsy\\:\\ 0\\.004693023593864955\ \(0\)\
\-\ typically\\:\\ 0\\.0046693897360773565\ \(0\)\
\-\ sign\\:\\ 0\\.004582734522854599\ \(0\)\
\-\ that\\:\\ 0\\.004569599778819887\ \(0\)\
\-\ in\\:\\ 0\\.004566223856008954\ \(0\)\
\-\ benign\\:\\ 0\\.004565093447419817\ \(0\)\
\-\ headache\\:\\ 0\\.004543321110782969\ \(0\)\
\-\ less\\:\\ 0\\.004479783288425205\ \(0\)\
\-\ air\\:\\ 0\\.004475638740792517\ \(0\)\
\-\ type\\:\\ 0\\.00445917063211596\ \(0\)\
\-\ extending\\:\\ 0\\.004446933512135909\ \(0\)\
\-\ unremarkable\\:\\ 0\\.00437935978124158\ \(0\)\
\-\ spine\\:\\ 0\\.004356197439636762\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.004303462835049137\ \(0\)\
\-\ plain\\:\\ 0\\.004296073858651834\ \(0\)\
\-\ should\\:\\ 0\\.00421704108651517\ \(0\)\
\-\ known\\:\\ 0\\.004185837592049256\ \(0\)\
\-\ and\\:\\ 0\\.004179775674896713\ \(0\)\
\-\ any\\:\\ 0\\.0041653793081614454\ \(0\)\
\-\ such\\:\\ 0\\.004135190077153022\ \(0\)\
\-\ approximately\\:\\ 0\\.004092597254730005\ \(0\)\
\-\ medical\\:\\ 0\\.004070139009390099\ \(0\)\
\-\ severe\\:\\ 0\\.004070139009390099\ \(0\)\
\-\ age\\:\\ 0\\.00402617697452679\ \(0\)\
\-\ usually\\:\\ 0\\.00401691680165133\ \(0\)\
\-\ there\\:\\ 0\\.003937199865216684\ \(0\)\
\-\ primary\\:\\ 0\\.003918551490550614\ \(0\)\
\-\ 5\\:\\ 0\\.0038702173722045875\ \(0\)\
\-\ not\\:\\ 0\\.0038229680239688403\ \(0\)\
\-\ appearance\\:\\ 0\\.0037831371156883\ \(0\)\
\-\ abnormal\\:\\ 0\\.0037725886072986245\ \(0\)\
\-\ head\\:\\ 0\\.00375170481512987\ \(0\)\
\-\ all\\:\\ 0\\.0037413676306985925\ \(0\)\
\-\ region\\:\\ 0\\.003736224809967976\ \(0\)\
\-\ chronic\\:\\ 0\\.003725990143818886\ \(0\)\
\-\ scan\\:\\ 0\\.00370320659509749\ \(0\)\
\-\ mass\\:\\ 0\\.0036794458419429246\ \(0\)\
\-\ if\\:\\ 0\\.0035893861204034606\ \(0\)\
\-\ cell\\:\\ 0\\.003573128036503849\ \(0\)\
\-\ lesions\\:\\ 0\\.003541115334897752\ \(0\)\
\-\ than\\:\\ 0\\.003466019899254294\ \(0\)\
\-\ these\\:\\ 0\\.0034424840432783904\ \(0\)\
\-\ of\\:\\ 0\\.0034265823764114242\ \(0\)\
\-\ on\\:\\ 0\\.0033617229676413066\ \(0\)\
\-\ symptoms\\:\\ 0\\.0032966834007711132\ \(0\)\
\-\ physical\\:\\ 0\\.0032453641943982017\ \(0\)\
\-\ chest\\:\\ 0\\.003165215170367676\ \(0\)\
\-\ tissue\\:\\ 0\\.003135326917109278\ \(0\)\
\-\ associated\\:\\ 0\\.0031214590741605293\ \(0\)\
\-\ or\\:\\ 0\\.0031006896252746365\ \(0\)\
\-\ tumor\\:\\ 0\\.003083950931286086\ \(0\)\
\-\ woman\\:\\ 0\\.0030555773180942825\ \(0\)\
\-\ present\\:\\ 0\\.002987629650049042\ \(0\)\
\-\ contrast\\:\\ 0\\.002960953075554033\ \(0\)\
\-\ \\,\\:\\ 0\\.0029333908028189035\ \(0\)\
\-\ exam\\:\\ 0\\.0029059348915627527\ \(0\)\
\-\ findings\\:\\ 0\\.002815537052306439\ \(0\)\
\-\ right\\:\\ 0\\.0027914294399703304\ \(0\)\
\-\ surgical\\:\\ 0\\.002780529056116801\ \(0\)\
\-\ presents\\:\\ 0\\.002702235751560257\ \(0\)\
\-\ seen\\:\\ 0\\.002613974636327694\ \(0\)\
\-\ has\\:\\ 0\\.0024840556818796875\ \(0\)\
\-\ with\\:\\ 0\\.002354573203047317\ \(0\)\
\-\ \\(\\:\\ 0\\.002236414013138887\ \(0\)\
\-\ \\)\\:\\ 0\\.0022090950220226167\ \(0\)\
\-\ normal\\:\\ 0\\.002073703490091488\ \(0\)\
\-\ \\.\\:\\ 0\\.0019783023212143432\ \(0\)\
\-\ from\\:\\ 0\\.0019604268005483164\ \(0\)\
\-\ an\\:\\ 0\\.0018292025762921516\ \(0\)\
\-\ year\\:\\ 0\\.0014800391165215399\ \(0\)\
\-\ old\\:\\ 0\\.0013543879208394035\ \(0\)\
